Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
Background & Aims: TMC435 is an investigational, once-daily, oral NS3/4A protease inhibitor currently in phase III development for the treatment of hepatitis C virus (HCV) infection. Phase I and II studies in patients infected with HCV genotype 1 have demonstrated that TMC435 is generally well...
Saved in:
Main Authors: | Moreno C., Berg T., Tanwandee T., Thongsawat S., Van Vlierberghe H., Zeuzem S., Lenz O., Peeters M., Sekar V., De Smedt G. |
---|---|
格式: | 雜誌 |
出版: |
2017
|
在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861188748&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/42832 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
相似書籍
-
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
由: Christophe Moreno, et al.
出版: (2018) -
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
由: Christophe Moreno, et al.
出版: (2018) -
LTI, Laguna-Calamba TMC microwave link design
由: Sabah, Nesser Moh'd
出版: (1998) -
EXPLORING THE MOLECULAR BASIS OF DRUG RESISTANCE TO PA-824 AND TMC207
由: HANA LEI HAVER
出版: (2013) -
The 4th International Workshop on Talent and Management Computing (TMC'2023): Editorial
由: ZHU, Hengshu, et al.
出版: (2023)